About
Ines joined SHTAC in 2020, first as a Consultant and then as a Senior Research Assistant in Health Technology Assessment & Modelling.
After graduating from University of Coimbra with a master’s degree in Pharmaceutical Sciences in 2014, Ines worked as a research assistant in health technology assessment for a consultancy firm in Portugal for 5 years, in which she developed skills related to pharmaceutical health assessment, health economics and outcomes research across multiple therapeutic areas.
Since 2017, Ines has been investigating in which extent pharmacoeconomic studies of ophthalmic drugs provide solid and trustworthy ground for responsible social political and economic decision making, as part of her PhD.
Since joining SHTAC, Inês has been contributing to evidence reviews of submissions to the NICE Single Technology Assessment Programmes and to evidence assessment of diagnostic procedures for submission to NICE
Research
Research groups
Research interests
- 1. Health economics & modelling
- 2. Quality of life
- 3. Ophthalmic drugs
Current research
Title: Real-world outcomes and economic evaluation predictions: do they correlate? A study with ophthalmic drugs.
Objective:
- To clarify the role of pharmacoeconomic studies as a tool to inform policy decision making of ophthalmic drugs.
Subobjectives:
- Identify pharmacoeconomic studies of ophthalmic drugs, characterize them, assess their methodological quality – Current status: complete.
- Analyze the pharmacoeconomic studies of ophthalmic drugs by exploring the effectiveness outcomes used and the sources of evidence that supports them – Current status: complete.
- Evaluate if the results provided by these pharmacoeconomic studies reflect the results from clinical practice – Current status: still to do.
Research question: Are the real-world outcomes of ophthalmic drugs in line with the results of pharmacoeconomic studies that supported their financing decisions?
Main contributions: Considering an aging population and the consequent social and economic impact of eye disorders and given the limitations of data supporting drugs’ reimbursement, it is relevant to determine in which extent pharmacoeconomic studies of ophthalmic drugs provide solid and trustworthy ground for responsible social political and economic decision making.